These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

322 related articles for article (PubMed ID: 18006217)

  • 21. Different patterns of 5alpha-reductase expression, cellular distribution, and testosterone metabolism in human follicular dermal papilla cells.
    Liu S; Yamauchi H
    Biochem Biophys Res Commun; 2008 Apr; 368(4):858-64. PubMed ID: 18258185
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Levels of 5alpha-reductase type 1 and type 2 are increased in localized high grade compared to low grade prostate cancer.
    Thomas LN; Douglas RC; Lazier CB; Gupta R; Norman RW; Murphy PR; Rittmaster RS; Too CK
    J Urol; 2008 Jan; 179(1):147-51. PubMed ID: 17997435
    [TBL] [Abstract][Full Text] [Related]  

  • 23. An overview on 5alpha-reductase inhibitors.
    Aggarwal S; Thareja S; Verma A; Bhardwaj TR; Kumar M
    Steroids; 2010 Feb; 75(2):109-53. PubMed ID: 19879888
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The dual 5-alpha-reductase inhibitor dutasteride induces atrophic changes and decreases relative cancer volume in human prostate.
    Iczkowski KA; Qiu J; Qian J; Somerville MC; Rittmaster RS; Andriole GL; Bostwick DG
    Urology; 2005 Jan; 65(1):76-82. PubMed ID: 15667867
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The loss of 5alpha-reductase type I and type II mRNA expression in metastatic prostate cancer to bone and lymph node metastasis.
    Habib FK; Ross M; Bayne CW; Bollina P; Grigor K; Chapman K
    Clin Cancer Res; 2003 May; 9(5):1815-9. PubMed ID: 12738739
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Effect of dutasteride on reduction of plasma DHT following finasteride therapy in patients with benign prostatic hyperplasia].
    Botto H; Lan O; Poulain JE; Comenducci A
    Prog Urol; 2005 Dec; 15(6):1090-5. PubMed ID: 16429658
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Update on prostate cancer chemoprevention.
    Lowe JF; Frazee LA
    Pharmacotherapy; 2006 Mar; 26(3):353-9. PubMed ID: 16503715
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of dutasteride on prostate growth in the large probasin-large T antigen mouse model of prostate cancer.
    Shao TC; Li H; Ittmann M; Cunningham GR
    J Urol; 2007 Oct; 178(4 Pt 1):1521-7. PubMed ID: 17707058
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The effect of finasteride and dutasteride on the growth of WPE1-NA22 prostate cancer xenografts in nude mice.
    Opoku-Acheampong AB; Nelsen MK; Unis D; Lindshield BL
    PLoS One; 2012; 7(1):e29068. PubMed ID: 22242155
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacogenetic analysis of human steroid 5 alpha reductase type II: comparison of finasteride and dutasteride.
    Makridakis N; Reichardt JK
    J Mol Endocrinol; 2005 Jun; 34(3):617-23. PubMed ID: 15956333
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacological approaches to reducing the risk of prostate cancer.
    Rittmaster RS; Fleshner NE; Thompson IM
    Eur Urol; 2009 May; 55(5):1064-73. PubMed ID: 19200641
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Differential expression of steroid 5alpha-reductase isozymes and association with disease severity and angiogenic genes predict their biological role in prostate cancer.
    Das K; Lorena PD; Ng LK; Lim D; Shen L; Siow WY; Teh M; Reichardt JK; Salto-Tellez M
    Endocr Relat Cancer; 2010 Sep; 17(3):757-70. PubMed ID: 20519274
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The rationale for inhibiting 5alpha-reductase isoenzymes in the prevention and treatment of prostate cancer.
    Tindall DJ; Rittmaster RS
    J Urol; 2008 Apr; 179(4):1235-42. PubMed ID: 18280514
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A review of the clinical efficacy and safety of 5alpha-reductase inhibitors for the enlarged prostate.
    Naslund MJ; Miner M
    Clin Ther; 2007 Jan; 29(1):17-25. PubMed ID: 17379044
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Differential expression of 5 alpha-reductase isoenzymes in the human prostate and prostatic carcinomas.
    Bonkhoff H; Stein U; Aumüller G; Remberger K
    Prostate; 1996 Oct; 29(4):261-7. PubMed ID: 8876709
    [TBL] [Abstract][Full Text] [Related]  

  • 36. High-grade prostate cancer and finasteride.
    Lebdai S; Bigot P; Azzouzi AR
    BJU Int; 2010 Feb; 105(4):456-9. PubMed ID: 19930174
    [TBL] [Abstract][Full Text] [Related]  

  • 37. 5alpha-Reductase inhibitor treatment of prostatic diseases: background and practical implications.
    Dörsam J; Altwein J
    Prostate Cancer Prostatic Dis; 2009; 12(2):130-6. PubMed ID: 19030020
    [TBL] [Abstract][Full Text] [Related]  

  • 38. 5alpha-reductase isozymes and androgen actions in the prostate.
    Zhu YS; Imperato-McGinley JL
    Ann N Y Acad Sci; 2009 Feb; 1155():43-56. PubMed ID: 19250191
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Inhibition of fatty acid synthase activity in prostate cancer cells by dutasteride.
    Schmidt LJ; Ballman KV; Tindall DJ
    Prostate; 2007 Jul; 67(10):1111-20. PubMed ID: 17477363
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Expression of type I and type II 5alpha-reductase isoenzymes in prostate cancer tissues].
    Ye L; Zhang Y; Fang Z
    Zhonghua Yi Xue Za Zhi; 2001 Dec; 81(24):1504-7. PubMed ID: 16200776
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.